Patent intelligence · US
US 12076316
Levorphanol prodrugs and processes for making and using them
Levorphanol prodrugs and processes for making and using them
Patent details — US 12076316
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 3, 2024
- Expiration
- Aug 29, 2044
- Applicant
- Zevra Therapeutics, Inc.
- Claims
- 15
- CPC classes
- A61K, A61K31/485, A61K45/06, A61K47/542
Quick answer
US 12076316 (Levorphanol prodrugs and processes for making and using them) is held by Zevra Therapeutics, Inc.. Status: granted. Granted Sep 3, 2024. Expires Aug 29, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Zevra Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K31/485, A61K45/06, A61K47/542, A61K47/551, A61K47/60
More from Zevra Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12251445
Gamma-hydroxybutyrate delivering compounds and processes for making and using them
granted -
US 12091386
D-amphetamine compounds, compositions, and processes for making and using the same
granted -
US 12012384
Dextrorphan prodrugs and processes for making and using them
granted -
US 11938125
Use of Hsp70 as a regulator of enzymatic activity
granted
Frequently asked questions
What is US patent 12076316?
US 12076316 (Levorphanol prodrugs and processes for making and using them) is held by Zevra Therapeutics, Inc.. Status: granted. Granted Sep 3, 2024. Expires Aug 29, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12076316?
Zevra Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 12076316 expire?
Our index shows an expiration date of Aug 29, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.